Unknown

Dataset Information

0

A plasma SNORD33 signature predicts platinum benefit in metastatic triple-negative breast cancer patients.

ABSTRACT:

SUBMITTER: Wang B 

PROVIDER: S-EPMC8764855 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Plasma CAMK2A predicts chemotherapy resistance in metastatic triple negative breast cancer.
| S-EPMC6958019 | biostudies-literature
Unknown Platinum-containing regimens for triple-negative metastatic breast cancer.
| S-EPMC8092567 | biostudies-literature
Unknown BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer.
| S-EPMC7382055 | biostudies-literature
Unknown A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients.
| S-EPMC5915573 | biostudies-literature
Unknown A gene signature predicts response to neoadjuvant chemotherapy in triple-negative breast cancer patients.
| S-EPMC6509059 | biostudies-literature
Unknown Three-microRNA expression signature predicts survival in triple-negative breast cancer.
| S-EPMC6923981 | biostudies-literature
Unknown Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
| S-EPMC6773427 | biostudies-literature
Unknown The 3'UTR signature defines a highly metastatic subgroup of triple-negative breast cancer.
| S-EPMC5312352 | biostudies-literature
Unknown A risk stratification model for predicting brain metastasis and brain screening benefit in patients with metastatic triple-negative breast cancer.
| S-EPMC7666757 | biostudies-literature
Unknown A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors.
| S-EPMC6930158 | biostudies-literature